At the University of California, San Francisco (UCSF), the team treating patients with bladder cancer and other genitourinary malignancies utilizes a multidisciplinary team approach to ensure care is coordinated, personalized, and patient-centered. This is particularly important when administering antibody-drug conjugates, a promising tool for some patients with muscle-invasive bladder cancer that comes with a high risk of adverse events (AEs). In this episode, CANCER BUZZ speaks with Terence Friedlander, MD, and Iva Petrovchich Colón, NP, both part of the team treating bladder cancer at UCSF, about how their cancer program manages the toxicity profile of ADCs in order to prioritize patient outcomes and quality of life.
“The median onset is in the mid 60s, and folks who are in their 60s are more mature, they may have more comorbidities, more medical problems, and we have to be really sensitive to that.” —Terence Friedlander, MD
“It takes a village and having that having open and direct communication is key.” —Iva Colón, NP
Guests:
Terence Friedlander, MD
Robert and Virginia O'Reilly Family Professor of Medicine
Chief of Hematology-Oncology, Zuckerberg San Francisco General Hospital
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Iva Colón, NP
Nurse Practitioner, Genitourinary Medical Oncology
UCSF Health Genitourinary Medical Oncology Mission Bay
San Francisco, CA
Resources:
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
